(Q54024534)

23 May 2018

title

Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. (English)

1 reference

23 May 2018

0 references

de Boer WA

1

1 reference

23 May 2018

Borody TJ

series ordinal

2

1 reference

23 May 2018

publication date

1 November 2000

1 reference

23 May 2018

Digestive and Liver Disease

published in

1 reference

23 May 2018

volume

32

1 reference

23 May 2018

issue

8

1 reference

23 May 2018

page(s)

673-675

1 reference

23 May 2018

Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Review article: nitroimidazole resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Regular review: treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

Therapy and diagnostic tests used for Helicobacter pylori infection in the Scandinavian countries in 1998

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2800%2980328-X

7 January 2021

10.1016/S1590-8658(00)80328-X

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018